CoChat
Sign Up
Cited by 52

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

The impact of CFTR modulator therapies on CF airway microbiology

Rogers, Geraint B., Taylor, Steven L., Hoffman, Lucas R., Burr, Lucy D.·2020·Journal of Cystic Fibrosis
DOI 10.1016/j.jcf.2019.07.008PMC PMC7025810
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jcf.2019.07.008

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 66

  1. Gentzsch, 2018, Ion channel modulators in cystic fibrosis, Chest, 154, 383, 10.1016/j.chest.2018.04.036 · DOI
  2. Andersen, 1938, Cystic fibrosis of the pancreas and its relation to celiac diseasea clinical and pathologic study, Am J Dis Child, 56, 344, 10.1001/archpedi.1938.01980140114013 · DOI
  3. Castellani, 2018, ECFS best practice guidelines: the 2018 revision, J Cyst Fibros, 17, 153, 10.1016/j.jcf.2018.02.006 · DOI · Paper page
  4. Fuchs, 1994, Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group N, Engl J Med, 331, 637, 10.1056/NEJM199409083311003 · DOI
  5. Wark, 2003, Nebulised hypertonic saline for cystic fibrosis, Cochrane Database Syst Rev, 1, 10.1002/14651858.CD001506 · DOI
  6. Ramsey, 1999, Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic fibrosis inhaled tobramycin study group, N Engl J Med, 340, 23, 10.1056/NEJM199901073400104 · DOI
  7. McCoy, 2008, Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis, Am J Respir Crit Care Med, 178, 921, 10.1164/rccm.200712-1804OC · DOI
  8. Southern, 2012, Macrolide antibiotics for cystic fibrosis, Cochrane Database Syst Rev
  9. Ivanov, 2018, Targeted sequencing reveals complex, phenotype-correlated genotypes in cystic fibrosis, BMC Med Genomics, 11, 13, 10.1186/s12920-018-0328-z · DOI
  10. Marson, 2016, Classification of CFTR mutation classes, Lancet Respir Med, 4, e37, 10.1016/S2213-2600(16)30188-6 · DOI
  11. McKone, 2003, Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study, Lancet, 361, 1671, 10.1016/S0140-6736(03)13368-5 · DOI
  12. Rowe, 2014, Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis, Am J Respir Crit Care Med, 190, 175, 10.1164/rccm.201404-0703OC · DOI · Paper page
  13. Skilton, 2019, Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis, Cochrane Database Syst Rev
  14. Wainwright, 2015, Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR, N Engl J Med, 373, 220, 10.1056/NEJMoa1409547 · DOI · Paper page
  15. Taylor-Cousar, 2017, Tezacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del, N Engl J Med, 377, 2013, 10.1056/NEJMoa1709846 · DOI · Paper page
  16. Rowe, 2017, Tezacaftor-Ivacaftor in residual-function heterozygotes with cystic fibrosis, N Engl J Med, 377, 2024, 10.1056/NEJMoa1709847 · DOI · Paper page
  17. Clancy, 2019, CFTR modulator theratyping: current status, gaps and future directions, J Cyst Fibros, 18, 22, 10.1016/j.jcf.2018.05.004 · DOI
  18. Keating, 2018, VX-445-Tezacaftor-Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles, N Engl J Med, 379, 1612, 10.1056/NEJMoa1807120 · DOI · Paper page
  19. Davies, 2018, VX-659-Tezacaftor-Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles, N Engl J Med, 379, 1599, 10.1056/NEJMoa1807119 · DOI · Paper page
  20. Pillarisetti, 2011, Infection, inflammation, and lung function decline in infants with cystic fibrosis, Am J Respir Crit Care Med, 184, 75, 10.1164/rccm.201011-1892OC · DOI
  21. Ranganathan, 2011, Evolution of pulmonary inflammation and nutritional status in infants and young children with cystic fibrosis, Thorax, 66, 408, 10.1136/thx.2010.139493 · DOI
  22. Sagel, 2012, Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis, Am J Respir Crit Care Med, 186, 857, 10.1164/rccm.201203-0507OC · DOI
  23. Elizur, 2008, Airway inflammation in cystic fibrosis, Chest, 133, 489, 10.1378/chest.07-1631 · DOI
  24. Ratjen, 2003, Cystic fibrosis, Lancet, 361, 681, 10.1016/S0140-6736(03)12567-6 · DOI · Paper page
  25. Treggiari, 2007, Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis, Pediatr Pulmonol, 42, 751, 10.1002/ppul.20665 · DOI
  26. Frayman, 2017, The lower airway microbiota in early cystic fibrosis lung disease: a longitudinal analysis, Thorax, 72, 1104, 10.1136/thoraxjnl-2016-209279 · DOI
  27. Muhlebach, 2018, Initial acquisition and succession of the cystic fibrosis lung microbiome is associated with disease progression in infants and preschool children, PLoS Pathog, 14, 10.1371/journal.ppat.1006798 · DOI
  28. Frayman, 2018, Differences in the lower airway microbiota of infants with and without cystic fibrosis, J Cyst Fibros
  29. Pittman, 2017, Association of antibiotics, airway microbiome, and inflammation in infants with cystic fibrosis, Ann Am Thorac Soc, 14, 1548, 10.1513/AnnalsATS.201702-121OC · DOI
  30. Rogers, 2013, Interpreting infective microbiota: the importance of an ecological perspective, Trends Microbiol, 21, 271, 10.1016/j.tim.2013.03.004 · DOI · Paper page
  31. Zemanick, 2017, Airway microbiota across age and disease spectrum in cystic fibrosis, Eur Respir J, 50, 10.1183/13993003.00832-2017 · DOI
  32. Klepac-Ceraj, 2010, Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa, Environ Microbiol, 12, 1293, 10.1111/j.1462-2920.2010.02173.x · DOI
  33. Goss, 2007, Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis, Thorax, 62, 360, 10.1136/thx.2006.060889 · DOI
  34. Lipuma, 2010, The changing microbial epidemiology in cystic fibrosis, Clin Microbiol Rev, 23, 299, 10.1128/CMR.00068-09 · DOI
  35. Donaldson, 2018, Tezacaftor/Ivacaftor in subjects with cystic fibrosis and Phe508del/Phe508del -CFTR or Phe508del/G551D-CFTR, Am J Respir Crit Care Med, 197, 214, 10.1164/rccm.201704-0717OC · DOI
  36. Hisert, 2017, Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections, Am J Respir Crit Care Med, 195, 1617, 10.1164/rccm.201609-1954OC · DOI
  37. Angrill, 2002, Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors, Thorax, 57, 15, 10.1136/thorax.57.1.15 · DOI
  38. Heeb, 2011, Quinolones: from antibiotics to autoinducers, FEMS Microbiol Rev, 35, 247, 10.1111/j.1574-6976.2010.00247.x · DOI
  39. Schneider, 2016, An "unlikely" pair: the antimicrobial synergy of polymyxin B in combination with the cystic fibrosis transmembrane conductance regulator drugs KALYDECO and ORKAMBI, ACS Infect Dis, 2, 478, 10.1021/acsinfecdis.6b00035 · DOI
  40. Reznikov, 2014, Antibacterial properties of the CFTR potentiator ivacaftor, J Cyst Fibros, 13, 515, 10.1016/j.jcf.2014.02.004 · DOI
  41. Payne, 2017, Activity of innate antimicrobial peptides and ivacaftor against clinical cystic fibrosis respiratory pathogens, Int J Antimicrob Agents, 50, 427, 10.1016/j.ijantimicag.2017.04.014 · DOI
  42. Cho, 2019, Ivacaftor, a cystic fibrosis transmembrane conductance regulator potentiator, enhances ciprofloxacin activity against pseudomonas aeruginosa, Am J Rhinol Allergy, 33, 129, 10.1177/1945892418815615 · DOI
  43. Bernarde, 2015, Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation, PLoS One, 10, 10.1371/journal.pone.0124124 · DOI
  44. Konstan, 2007, Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis, J Pediatr, 151, 134, 10.1016/j.jpeds.2007.03.006 · DOI
  45. Emerson, 2002, Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis, Pediatr Pulmonol, 34, 91, 10.1002/ppul.10127 · DOI
  46. Nixon, 2001, Clinical outcome after early pseudomonas aeruginosa infection in cystic fibrosis, J Pediatr, 138, 699, 10.1067/mpd.2001.112897 · DOI
  47. Heltshe, 2015, Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor, Clin Infect Dis, 60, 703, 10.1093/cid/ciu944 · DOI
  48. Siracusa, 2015, Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor, J Cyst Fibros, 14, 621, 10.1016/j.jcf.2015.05.009 · DOI
  49. Peleg, 2018, Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory microbiota composition, J Cyst Fibros, 17, 50, 10.1016/j.jcf.2017.08.002 · DOI
  50. Mena, 2008, Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation, J Bacteriol, 190, 7910, 10.1128/JB.01147-08 · DOI
  51. Cramer, 2011, Microevolution of the major common Pseudomonas aeruginosa clones C and PA14 in cystic fibrosis lungs, Environ Microbiol, 13, 1690, 10.1111/j.1462-2920.2011.02483.x · DOI
  52. Markussen, 2014, Environmental heterogeneity drives within-host diversification and evolution of Pseudomonas aeruginosa, MBio, 5, 10.1128/mBio.01592-14 · DOI
  53. Anderson, 2008, In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells, Infect Immun, 76, 1423, 10.1128/IAI.01373-07 · DOI
  54. Aspedon, 2006, Microarray analysis of the osmotic stress response in Pseudomonas aeruginosa, J Bacteriol, 188, 2721, 10.1128/JB.188.7.2721-2725.2006 · DOI
  55. Bagge, 2004, Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and beta-lactamase and alginate production, Antimicrob Agents Chemother, 48, 1175, 10.1128/AAC.48.4.1175-1187.2004 · DOI
  56. Cirz, 2006, Defining the pseudomonas aeruginosa SOS response and its role in the global response to the antibiotic ciprofloxacin, J Bacteriol, 188, 7101, 10.1128/JB.00807-06 · DOI
  57. Jones, 2010, Activation of the Pseudomonas aeruginosa AlgU regulon through mucA mutation inhibits cyclic AMP/Vfr signaling, J Bacteriol, 192, 5709, 10.1128/JB.00526-10 · DOI
  58. Wu, 2004, MucA-mediated coordination of type III secretion and alginate synthesis in Pseudomonas aeruginosa, J Bacteriol, 186, 7575, 10.1128/JB.186.22.7575-7585.2004 · DOI
  59. Folkesson, 2012, Adaptation of pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective, Nat Rev Microbiol, 10, 841, 10.1038/nrmicro2907 · DOI
  60. Smith, 2006, Genetic adaptation by pseudomonas aeruginosa to the airways of cystic fibrosis patients, Proc Natl Acad Sci U S A, 103, 8487, 10.1073/pnas.0602138103 · DOI · Paper page
  61. Lore, 2012, Cystic fibrosis-niche adaptation of Pseudomonas aeruginosa reduces virulence in multiple infection hosts, PLoS One, 7, 10.1371/journal.pone.0035648 · DOI
  62. Huse, 2010, Parallel evolution in Pseudomonas aeruginosa over 39,000 generations in vivo, MBio, 1, 10.1128/mBio.00199-10 · DOI
  63. Emerson, 2010, Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008, Pediatr Pulmonol, 45, 363, 10.1002/ppul.21198 · DOI
  64. Millar, 2009, Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985-2005, J Cyst Fibros, 8, 386, 10.1016/j.jcf.2009.08.003 · DOI
  65. Acosta, 2017, The evolving cystic fibrosis microbiome: a comparative cohort study spanning 16 years, Ann Am Thorac Soc, 14, 1288, 10.1513/AnnalsATS.201609-668OC · DOI
  66. Crull, 2016, Change in Pseudomonas aeruginosa prevalence in cystic fibrosis adults over time, BMC Pulm Med, 16, 176, 10.1186/s12890-016-0333-y · DOI

Cited by

Sorted by citations

Metadata

Authors
Rogers, G. B., Taylor, S. L., Hoffman, L. R., & Burr, L. D.
Venue
Journal of Cystic Fibrosis
Publisher
Elsevier BV
Published
2020-05
Volume
19
Issue
3
Pages
359-364
ISSN
1569-1993
DOI
10.1016/j.jcf.2019.07.008
PMC
PMC7025810
Cited by
52
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review